Evidence map›Paper›PMID 37094437›Full record

ArticleNeuroImage. Clinical2023

Degradation of EEG microstates patterns in subjective cognitive decline and mild cognitive impairment: Early biomarkers along the Alzheimer's Disease continuum?

Michael Lassi, Carlo Fabbiani, Salvatore Mazzeo, Rachele Burali, Alberto Arturo Vergani, Giulia Giacomucci, Valentina Moschini, Carmen Morinelli, Filippo Emiliani, Maenia Scarpino and 9 more

Registry-linked trialOpen access · goldAbstract read
In one paragraph

Article in NeuroImage. Clinical, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07402161 (Unraveling the SIGNature of ALzheimer's Disease), which is not on this map. Cited by 31 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
31citing papers in PubMed, 1 pooled it
8.1field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07402161 recruitingnot on this mapstarted 2025, after this paper: background citation

Unraveling the SIGNature of ALzheimer's Disease: Integrating Multimodal Biomarkers Through Machine Learning

TypeobservationalSponsorIRCCS Policlinico S. DonatoRan2025 to 2028Enrolled250ConditionsSubjective Cognitive Decline (SCD), Subjective Cognitive Complaints (SCCs), Subjective Cognitive Impairment, Subjective Cognitive Concerns
3 · Its place in the literature

Who cites it

31 citing papers in PubMed, 1 synthesis or guideline pooled it, 46 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 5 institutions in 2 countries.

Michael LassiThe BioRobotics Institute and Department of Excellence in Robotics and AI, Sant'Anna School of Advanced Studies, viale Rinaldo Piaggio 34, 56025 Pisa, Italy.
Carlo FabbianiIRCCS Fondazione Don Carlo Gnocchi, via di Scandicci, 269, 50143 Florence, Italy.
Salvatore MazzeoIRCCS Fondazione Don Carlo Gnocchi, via di Scandicci, 269, 50143 Florence, Italy; Department of Neuroscience, Psychology, Drug Research and Child Health, University of Florence, Careggi University Hospital, viale Gaetano Pieraccini, 6, 50139 Florence, Italy.
Rachele BuraliIRCCS Fondazione Don Carlo Gnocchi, via di Scandicci, 269, 50143 Florence, Italy.
Alberto Arturo VerganiThe BioRobotics Institute and Department of Excellence in Robotics and AI, Sant'Anna School of Advanced Studies, viale Rinaldo Piaggio 34, 56025 Pisa, Italy.
Giulia GiacomucciDepartment of Neuroscience, Psychology, Drug Research and Child Health, University of Florence, Careggi University Hospital, viale Gaetano Pieraccini, 6, 50139 Florence, Italy.
Valentina MoschiniDepartment of Neuroscience, Psychology, Drug Research and Child Health, University of Florence, Careggi University Hospital, viale Gaetano Pieraccini, 6, 50139 Florence, Italy.
Carmen MorinelliDipartimento Neuromuscolo-scheletrico e degli organi di senso, Careggi University Hospital, 50134 Florence, Italy.
Filippo EmilianiDepartment of Neuroscience, Psychology, Drug Research and Child Health, University of Florence, Careggi University Hospital, viale Gaetano Pieraccini, 6, 50139 Florence, Italy.
Maenia ScarpinoIRCCS Fondazione Don Carlo Gnocchi, via di Scandicci, 269, 50143 Florence, Italy.
Silvia BagnoliDepartment of Neuroscience, Psychology, Drug Research and Child Health, University of Florence, Careggi University Hospital, viale Gaetano Pieraccini, 6, 50139 Florence, Italy.
Assunta IngannatoDepartment of Neuroscience, Psychology, Drug Research and Child Health, University of Florence, Careggi University Hospital, viale Gaetano Pieraccini, 6, 50139 Florence, Italy.
Benedetta NacmiasIRCCS Fondazione Don Carlo Gnocchi, via di Scandicci, 269, 50143 Florence, Italy; Department of Neuroscience, Psychology, Drug Research and Child Health, University of Florence, Careggi University Hospital, viale Gaetano Pieraccini, 6, 50139 Florence, Italy.
Sonia PadiglioniRegional Referral Centre for Relational Criticalities - Tuscany Region, 50139 Florence, Italy.
Silvestro MiceraThe BioRobotics Institute and Department of Excellence in Robotics and AI, Sant'Anna School of Advanced Studies, viale Rinaldo Piaggio 34, 56025 Pisa, Italy; Bertarelli Foundation Chair in Translational Neuroengineering, Centre for Neuroprosthetics and Institute of Bioengineering, School of Engineering, École Polytechnique Fédérale de Lausanne (EPFL), 1015 Lausanne, Switzerland.
Sandro SorbiIRCCS Fondazione Don Carlo Gnocchi, via di Scandicci, 269, 50143 Florence, Italy; Department of Neuroscience, Psychology, Drug Research and Child Health, University of Florence, Careggi University Hospital, viale Gaetano Pieraccini, 6, 50139 Florence, Italy.
Antonello GrippoIRCCS Fondazione Don Carlo Gnocchi, via di Scandicci, 269, 50143 Florence, Italy.
Valentina BessiDepartment of Neuroscience, Psychology, Drug Research and Child Health, University of Florence, Careggi University Hospital, viale Gaetano Pieraccini, 6, 50139 Florence, Italy.
Alberto MazzoniThe BioRobotics Institute and Department of Excellence in Robotics and AI, Sant'Anna School of Advanced Studies, viale Rinaldo Piaggio 34, 56025 Pisa, Italy. Electronic address: alberto.mazzoni@santannapisa.it.
University of Florence · ITDon Carlo Gnocchi Foundation · ITPiaggio Aerospace (Italy) · ITScuola Superiore Sant'Anna · ITRegione Toscana

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Alzheimer's disease (AD) pathological changes may begin up to decades earlier than the appearance of the first symptoms of cognitive decline. Subjective cognitive decline (SCD) could be the first pre-clinical sign of possible AD, which might be followed by mild cognitive impairment (MCI), the initial stage of clinical cognitive decline. However, the neural correlates of these prodromic stages are not completely clear yet. Recent studies suggest that EEG analysis tools characterizing the cortical activity as a whole, such as microstates and cortical regions connectivity, might support a characterization of SCD and MCI conditions. Here we test this approach by performing a broad set of analyses to identify the prominent EEG markers differentiating SCD (n = 57), MCI (n = 46) and healthy control subjects (HC, n = 19). We found that the salient differences were in the temporal structure of the microstates patterns, with MCI being associated with less complex sequences due to the altered transition probability, frequency and duration of canonic microstate C. Spectral content of EEG, network connectivity, and spatial arrangement of microstates were instead largely similar in the three groups. Interestingly, comparing properties of EEG microstates in different cerebrospinal fluid (CSF) biomarkers profiles, we found that canonic microstate C displayed significant differences in topography in AD-like profile. These results show that the progression of dementia might be associated with a degradation of the cortical organization captured by microstates analysis, and that this leads to altered transitions between cortical states. Overall, our approach paves the way for the use of non-invasive EEG recordings in the identification of possible biomarkers of progression to AD from its prodromal states.

Indexed as

Alzheimer DiseaseCognitive DysfunctionBiomarkersElectroencephalographyHumansBiomarkersAlzheimer’s DiseaseEEGMicrostatesMild cognitive impairmentSubjective cognitive decline

Identifiers

PMID37094437
PMCPMC10149415
OpenAlexW4366416017

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.